NEW YORK, May 5, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company") (NASDAQ: PBYI) (ISIN: US74587V1070). Investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Puma and certain of its officers and/or directors have violated the federal securities laws.
On May 4, 2017, post-market, Puma disclosed the resignation of Dr. Robert Charnas, the Company's Senior Vice President, Regulatory Affairs, citing "health reasons." Dr. Charnas's resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration's scheduled review of Puma's breast cancer drug neratinib on May 24.
On this news, Puma's share price has fallen as much as $6.70, or 18.08%, during intraday trading on May 5, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-puma-biotechnology-inc--pbyi-300452328.html
SOURCE Pomerantz LLP